<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362886">
  <stage>Registered</stage>
  <submitdate>11/08/2012</submitdate>
  <approvaldate>14/08/2012</approvaldate>
  <actrnumber>ACTRN12612000853842</actrnumber>
  <trial_identification>
    <studytitle>A Prospective Randomized Controlled Trial Assessing the Efficacy of Withdrawing Alpha-blocker Following Initial Combination Therapy with  5-Alpha Reductase Inhibitor for Benign Prostatic Hyperplasia</studytitle>
    <scientifictitle>A Prospective Randomized Controlled Trial Assessing the Efficacy of Withdrawing Alpha-blocker Following Initial Combination Therapy with  5-Alpha Reductase Inhibitor for Benign Prostatic Hyperplasia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Benign Prostate Hyperplasia</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Tablet dutasteride 0.5mg daily, oral, 3 months</interventions>
    <comparator>Tablet Dutasteride 0.5mg daily Orally and Alpha blocker tablet alfuzosin 10mg daily taken orally simultaneously for 3 months</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>International Prostate Symptoms Score</outcome>
      <timepoint>Basline and 3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximal urinary Flow Rate via uroflowmeter equipment</outcome>
      <timepoint>baseline and 3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients with moderate or severe BPH based on IPSS score who were newly diagnosed and started on combination therapy or who were previously diagnosed and were already on combination therapy for a duration of not more than one year. All patients on combination therapy had a prostate size of more than 40g as assessed by digital rectal examination</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>All patients had a baseline PSA taken routinely and patients with a value higher than 4ng/ml underwent biopsy to screen for possible malignancy. Patients with PSA value less than 1.5ng/ml, prostate cancer and patients with recurrent urinary tract infections were excluded from our study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All patients recruited had undergone combination therapy with alpha-blocker and 5ARI (dutasteride) for a total period of one year. At the end of the combination therapy, all patientâ€™s IPSS score and uroflowmetry (Qmax) were measured and taken as baseline values. Patients were then randomly assigned to continue combination therapy for a further 12 weeks (DT64) or discontinue alpha-blocker (DT52+/-12) using closed envelope method. There was no placebo involved in this study. Therefore, both investigator and subjects were not blinded in this study.</concealment>
    <sequence>Simple randomization via computerized sequence generation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>102</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Universiti Kebangsaan Malaysia Medical Centre</primarysponsorname>
    <primarysponsoraddress>Universiti Kebangsaan Malaysia Medical Centre,
Bandar Tun Razak, 
56000 Cheras
Kuala Lumpur
Malaysia</primarysponsoraddress>
    <primarysponsorcountry>Malaysia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Universiti Kebangsaan Malaysia Medical Centre</fundingname>
      <fundingaddress>Universiti Kebangsaan Malaysia Medical Centre,
Bandar Tun Razak, 
56000 Cheras
Kuala Lumpur
Malaysia</fundingaddress>
      <fundingcountry>Malaysia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Combination therapy of alpha-blocker and 5-alpha-reductase inhibitor (5ARI) is effective for the treatment of benign prostate hyperplasia (BPH) but it is costly. This study aimed to assess the efficacy of withdrawing alpha-blocker following initial combination therapy with 5ARI.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Universiti Kebangsaan Malaysia Research and Ethics Committee</ethicname>
      <ethicaddress>Jalan Yaacob Latif, Bandar Tun Razak,
56000 Cheras,
Kuala Lumpur,
Malaysia</ethicaddress>
      <ethicapprovaldate>15/06/2010</ethicapprovaldate>
      <hrec>FF-197-2010</hrec>
      <ethicsubmitdate />
      <ethiccountry>Malaysia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Christopher C.K. Ho</name>
      <address>Department of Surgery,
Universiti Kebangsaan Malaysia Medical Centre,
Bandar Tun Razak,
56000 Cheras,
Kuala Lumpur,
Malaysia</address>
      <phone>+60126826599</phone>
      <fax>+60391456684</fax>
      <email>chrisckho2002@yahoo.com</email>
      <country>Malaysia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Christopher C.K. Ho</name>
      <address>Department of Surgery,
Universiti Kebangsaan Malaysia Medical Centre,
Bandar Tun Razak,
56000 Cheras,
Kuala Lumpur,
Malaysia</address>
      <phone>+60126826599</phone>
      <fax>+60391456684</fax>
      <email>chrisckho2002@yahoo.com</email>
      <country>Malaysia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Christopher C.K. Ho</name>
      <address>Department of Surgery,
Universiti Kebangsaan Malaysia Medical Centre,
Bandar Tun Razak,
56000 Cheras,
Kuala Lumpur,
Malaysia</address>
      <phone>+60126826599</phone>
      <fax>+60391456684</fax>
      <email>chrisckho2002@yahoo.com</email>
      <country>Malaysia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>